Get the Stockscreener App
16.32
2.64%
0.405
Moonlake Immunotherapeutics stock is traded at $16.32, with a volume of 529.75K.
It is up +2.64% in the last 24 hours and up +18.08% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$15.91
Open:
$15.88
24h Volume:
529.75K
Relative Volume:
0.21
Market Cap:
$1.16B
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-7.0935
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
+0.00%
1M Performance:
+18.08%
6M Performance:
-70.35%
1Y Performance:
-63.62%
1-Day Range:
$15.86
$16.45
1-Week Range:
$15.20
$16.86
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
16.32 | 1.13B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.92 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.24 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.83 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.85 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.40 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
(MLTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Risk Analysis: What is the implied volatility of JWEL2025 Bull vs Bear & High Yield Stock Recommendations - baoquankhu1.vn
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.6%Here's What Happened - MarketBeat
Zacks Research Downgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Strong Sell - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab - MSN
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
MoonLake shares surge after FDA outlines approval route for HS therapy - MSN
Forecast Cut: Can TRINI deliver alphaRate Cut & Risk Managed Investment Entry Signals - baoquankhu1.vn
MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials - simplywall.st
MoonLake Immunotherapeutics (MLTX) Valuation After FDA BLA Green Light And Split Analyst Reactions - simplywall.st
Moonlake surges as no additional studies are required for lead drug - MSN
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - TMX Newsfile
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's Why - MarketBeat
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns By Investing.com - Investing.com South Africa
MoonLake downgraded to Sell at Goldman Sachs (MLTX:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades MoonLake Immunotherapeutics(MLTX.US) to Sell Rating, Raises Target Price to $10 - 富途资讯
Goldman Sachs Downgrades MLTX, Raises Price Target to $10.00 | M - GuruFocus
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns - Investing.com Canada
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs - TipRanks
MACD Signal: Is MoonLake Immunotherapeutics stock suitable for long term investingTrade Risk Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Stop Loss: Is IGMS benefiting from interest rate changes2025 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Exit Recap: Will MoonLake Immunotherapeutics stock continue upward momentumOil Prices & Safe Capital Growth Stock Tips - moha.gov.vn
Death Cross: How is MoonLake Immunotherapeutics managing supply chain issues2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Buyback Watch: What is the Moat Score of MoonLake ImmunotherapeuticsMarket Sentiment Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
Guidance Update: Why MoonLake Immunotherapeutics stock could rally in 2025Take Profit & AI Powered Market Trend Analysis - Bộ Nội Vụ
Published on: 2026-01-13 06:01:31 - Улправда
(MLTX) Risk Channels and Responsive Allocation - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.3%Time to Sell? - MarketBeat
MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations - MSN
Why MoonLake Immunotherapeutics (MLTX) Is Up 54.7% After FDA Opens Path to HS BLA Filing - simplywall.st
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
BTIG Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 - 富途资讯
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Clears Existing Data For Sonelokimab BLA In Hidradenitis Suppurativa - simplywall.st
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations - Stocktwits
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $20 to $45 - 富途牛牛
MoonLake Options Trading: A Deep Dive into Market Sentiment - Benzinga
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 9.6%Time to Buy? - MarketBeat
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - BioPharma Dive
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation - FinancialContent
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug - Citeline News & Insights
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Buy Rating at HC Wainwright - MarketBeat
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission (NASDAQ:MLTX) - Seeking Alpha
MLTX Analyst Rating: HC Wainwright & Co. Raises Price Target to $32.00 | MLTX Stock News - GuruFocus
BTIG Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
Moonlake Immunotherapeutics stock upgraded to Buy at BTIG on FDA feedback - Investing.com Nigeria
Will MoonLake's Clinical Milestones Send Investors Over The Moon? - RTTNews
Will MoonLake Immunotherapeutics stock benefit from AI adoptionJuly 2025 Update & High Conviction Trade Alerts - ulpravda.ru
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street By Investing.com - Investing.com South Africa
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
2.05%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):